Menu

Back

()

Key Publications

Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.

DOI: http://doi.org/10.1177/13524585241233177
Journal: Multiple Sclerosis Journal
E-pub date: 1 Jul 2024
Authors: CE McMurran, T Mukherjee, JWL Brown, AJ Coles, NG Cunniffe

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

DOI: http://doi.org/10.1177/17562864231194823
Journal: Ther Adv Neurol Disord
E-pub date: 1 Aug 2023
Authors: AJ Coles, A Achiron, A Traboulsee, BA Singer, C Pozzilli, C Oreja-Guevara, G Giovannoni, G Comi, MS Freedman, T Ziemssen, D Shiota, AM Rawlings, AT Wong, M Chirieac, X Montalban

Remyelination varies between and within lesions in multiple sclerosis following bexarotene.

DOI: http://doi.org/10.1002/acn3.51662
Journal: Ann Clin Transl Neurol
E-pub date: 1 Oct 2022
Authors: JWL Brown, F Prados, DR Altmann, B Kanber, J Stutters, NG Cunniffe, JL Jones, ZG Georgieva, EJ Needham, C Daruwalla, CG Wheeler-Kingshott, P Connick, S Chandran, R Franklin, D MacManus, R Samson, A Coles, D Chard

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent.

DOI: http://doi.org/10.1002/acn3.51595
Journal: Ann Clin Transl Neurol
E-pub date: 1 Jul 2022
Authors: CE McMurran, T Mukherjee, JWL Brown, AW Michell, DT Chard, RJM Franklin, AJ Coles, NG Cunniffe

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.

DOI: http://doi.org/10.1177/13524585211061335
Journal: Mult Scler
E-pub date: 1 Apr 2022
Authors: AJ Coles, JL Jones, P Vermersch, A Traboulsee, AD Bass, A Boster, A Chan, G Comi, Ó Fernández, G Giovannoni, E Kubala Havrdova, C LaGanke, X Montalban, C Oreja-Guevara, F Piehl, H Wiendl, T Ziemssen

Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.

DOI: http://doi.org/10.1016/j.msard.2021.103458
Journal: Mult Scler Relat Disord
E-pub date: 1 Jan 2022
Authors: A Garjani, S Patel, D Bharkhada, W Rashid, A Coles, GR Law, N Evangelou

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

DOI: http://doi.org/10.1016/S1474-4422(21)00179-4
Journal: Lancet Neurol
E-pub date: 1 Sep 2021
Authors: JWL Brown, NG Cunniffe, F Prados, B Kanber, JL Jones, E Needham, Z Georgieva, D Rog, OR Pearson, J Overell, D MacManus, RS Samson, J Stutters, C Ffrench-Constant, CAM Gandini Wheeler-Kingshott, C Moran, PD Flynn, AW Michell, RJM Franklin, S Chandran, DR Altmann, DT Chard, P Connick, AJ Coles

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.

DOI: http://doi.org/10.1177/1756286420982134
Journal: Ther Adv Neurol Disord
E-pub date: 1 Aug 2021
Authors: AJ Coles, DL Arnold, AD Bass, AL Boster, DAS Compston, Ó Fernández, EK Havrdová, K Nakamura, A Traboulsee, T Ziemssen, A Jacobs, DH Margolin, X Huang, N Daizadeh, MC Chirieac, KW Selmaj

The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro.

DOI: http://doi.org/10.3389/fimmu.2021.712241
Journal: Front Immunol
E-pub date: 1 Aug 2021
Authors: CM Gaunt, DB Rainbow, RJ Mackenzie, LB Jarvis, HS Mousa, N Cunniffe, Z Georgieva, JW Brown, AJ Coles, JL Jones

Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.

DOI: http://doi.org/10.1136/jnnp-2020-324286
Journal: J Neurol Neurosurg Psychiatry
E-pub date: 1 Mar 2021
Authors: N Cunniffe, KA Vuong, D Ainslie, D Baker, J Beveridge, S Bickley, P Camilleri, M Craner, D Fitzgerald, AG de la Fuente, G Giovannoni, E Gray, L Hazlehurst, R Kapoor, R Kaur, D Kozlowski, B Lumicisi, D Mahad, B Neumann, A Palmer, L Peruzzotti-Jametti, S Pluchino, J Robertson, A Rothaul, L Shellard, KJ Smith, A Wilkins, A Williams, A Coles

Promoting remyelination in multiple sclerosis.

DOI: http://doi.org/10.1007/s00415-019-09421-x
Journal: J Neurol
E-pub date: 1 Jan 2021
Authors: N Cunniffe, A Coles

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.

DOI: http://doi.org/10.1007/s00415-020-09983-1
Journal: J Neurol
E-pub date: 1 Nov 2020
Authors: B Steingo, Y Al Malik, AD Bass, R Berkovich, M Carraro, Ó Fernández, C Ionete, L Massacesi, SG Meuth, DD Mitsikostas, G Pardo, RF Simm, A Traboulsee, Z Choudhry, N Daizadeh, DAS Compston, CAMMS223, CAMMS03409, and TOPAZ Investigators

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

DOI: http://doi.org/10.1093/brain/awaa231
Journal: Brain
E-pub date: 1 Sep 2020
Authors: I Roos, E Leray, F Frascoli, R Casey, JWL Brown, D Horakova, EK Havrdova, M Trojano, F Patti, G Izquierdo, S Eichau, M Onofrj, A Lugaresi, A Prat, M Girard, P Grammond, P Sola, D Ferraro, S Ozakbas, R Bergamaschi, MJ Sá, E Cartechini, C Boz, F Granella, R Hupperts, M Terzi, J Lechner-Scott, D Spitaleri, V Van Pesch, A Soysal, J Olascoaga, J Prevost, E Aguera-Morales, M Slee, T Csepany, R Turkoglu, Y Sidhom, R Gouider, B Van Wijmeersch, P McCombe, R Macdonell, A Coles, CB Malpas, H Butzkueven, S Vukusic, T Kalincik, MSBase, OFSEP investigators

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

DOI: http://doi.org/10.1177/1352458519852093
Journal: Mult Scler
E-pub date: 31 Aug 2020
Authors: JWL Brown, F Prados Carrasco, A Eshaghi, CH Sudre, T Button, M Pardini, RS Samson, S Ourselin, CAG Wheeler-Kingshott, JL Jones, AJ Coles, DT Chard

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

DOI: http://doi.org/10.1016/S1474-4422(20)30067-3
Journal: Lancet Neurol
E-pub date: 1 Apr 2020
Authors: A He, B Merkel, JWL Brown, L Zhovits Ryerson, I Kister, CB Malpas, S Sharmin, D Horakova, E Kubala Havrdova, T Spelman, G Izquierdo, S Eichau, M Trojano, A Lugaresi, R Hupperts, P Sola, D Ferraro, J Lycke, F Grand'Maison, A Prat, M Girard, P Duquette, C Larochelle, A Svenningsson, T Petersen, P Grammond, F Granella, V Van Pesch, R Bergamaschi, C McGuigan, A Coles, J Hillert, F Piehl, H Butzkueven, T Kalincik, MSBase study group

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

DOI: http://doi.org/10.1186/s13063-019-3336-1
Journal: Trials
E-pub date: 7 Jun 2019
Authors: B Lennox, K Yeeles, PB Jones, M Zandi, E Joyce, L-M Yu, G Tomei, R Pollard, S-A Vincent, M Shimazaki, I Cairns, F Dowling, T Kabir, TRE Barnes, A Lingford Hughes, AA Hosseini, T Harrower, C Buckley, A Coles

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

DOI: http://doi.org/10.1001/jama.2018.20588
Journal: JAMA
E-pub date: 15 Jan 2019
Authors: JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, M Girard, P Duquette, M Trojano, A Lugaresi, R Bergamaschi, P Grammond, R Alroughani, R Hupperts, P McCombe, V Van Pesch, P Sola, D Ferraro, F Grand'Maison, M Terzi, J Lechner-Scott, S Flechter, M Slee, V Shaygannejad, E Pucci, F Granella, V Jokubaitis, M Willis, C Rice, N Scolding, A Wilkins, OR Pearson, T Ziemssen, M Hutchinson, K Harding, J Jones, C McGuigan, H Butzkueven, T Kalincik, N Robertson, MSBase Study Group

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.

DOI: http://doi.org/10.1210/jc.2018-00359
Journal: J Clin Endocrinol Metab
E-pub date: 1 Aug 2018
Authors: N Pariani, M Willis, I Muller, S Healy, T Nasser, A McGowan, G Lyons, J Jones, K Chatterjee, C Dayan, N Robertson, A Coles, C Moran

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

DOI: http://doi.org/10.1172/jci.insight.93739
Journal: JCI Insight
E-pub date: 17 Aug 2017
Authors: ML Pekalski, AR García, RC Ferreira, DB Rainbow, DJ Smyth, M Mashar, J Brady, N Savinykh, XC Dopico, S Mahmood, S Duley, HE Stevens, NM Walker, AJ Cutler, F Waldron-Lynch, DB Dunger, C Shannon-Lowe, AJ Coles, JL Jones, C Wallace, JA Todd, LS Wicker

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

DOI: http://doi.org/10.1016/S1474-4422(17)30007-8
Journal: Lancet Neurol
E-pub date: 1 Apr 2017
Authors: T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, A Wilkins, O Pearson, T Ziemssen, M Hutchinson, C McGuigan, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, G Izquierdo, A Lugaresi, A Prat, M Girard, P Duquette, P Grammond, R Alroughani, E Pucci, P Sola, R Hupperts, J Lechner-Scott, M Terzi, V Van Pesch, C Rozsa, F Grand'Maison, C Boz, F Granella, M Slee, D Spitaleri, J Olascoaga, R Bergamaschi, F Verheul, S Vucic, P McCombe, S Hodgkinson, JL Sanchez-Menoyo, R Ampapa, M Simo, T Csepany, C Ramo, E Cristiano, M Barnett, H Butzkueven, A Coles, MSBase Study Group

Alemtuzumab treatment of multiple sclerosis.

DOI: http://doi.org/10.1055/s-0033-1343797
Journal: Semin Neurol
E-pub date: 1 Feb 2013
Authors: AJ Coles

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

DOI: http://doi.org/10.1212/WNL.0b013e31824e8ee7
Journal: Neurology
E-pub date: 3 Apr 2012
Authors: AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, A Skoromets, I Stolyarov, A Bass, H Sullivan, DH Margolin, SL Lake, S Moran, J Palmer, MS Smith, DAS Compston

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

DOI: http://doi.org/10.1016/S1474-4422(11)70020-5
Journal: The Lancet Neurology
E-pub date: 1 Apr 2011
Authors: AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, AD-D Bass, DR Wynn, DH Margolin, SL Lake, S Moran, J Palmer, MS Smith, DAS Compston

A novel strategy to reduce the immunogenicity of biological therapies.

DOI: http://doi.org/10.4049/jimmunol.1000422
Journal: J Immunol
E-pub date: 1 Jul 2010
Authors: J Somerfield, GA Hill-Cawthorne, A Lin, MS Zandi, C McCarthy, JL Jones, M Willcox, D Shaw, SAJ Thompson, AS Compston, G Hale, H Waldmann, AJ Coles

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

DOI: http://doi.org/10.1172/JCI37878
Journal: J Clin Invest
E-pub date: 1 Jul 2009
Authors: JL Jones, C-L Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, A Walton, SJ Sawcer, A Compston, AJ Coles

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

DOI: http://doi.org/10.1056/NEJMoa0802670
Journal: N Engl J Med
E-pub date: 23 Oct 2008
Authors: CAMMS223 Trial Investigators, AJ Coles, DAS Compston, KW Selmaj, SL Lake, S Moran, DH Margolin, K Norris, PK Tandon

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

DOI: http://doi.org/10.1093/brain/119.1.225
Journal: Brain
E-pub date: 1 Feb 1996
Authors: T Moreau, A Coles, M Wing, J Isaacs, G Hale, H Waldmann, A Compston

Publications

Chasing MOG antibodies down … assays and lumbar punctures.

DOI: http://doi.org/10.1093/brain/awad271
Journal: Brain
E-pub date: 1 Sep 2023
Authors: AJ Coles

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

DOI: http://doi.org/10.1101/2023.04.03.23287902
Journal:
E-pub date: 1 Aug 2023
Authors: B Michael, C Dunai, E Needham, K Tharmaratnam, R Williams, Y Huang, S Boardman, J Clark, P Sharma, K Subramaniam, G Wood, C Collie, R Digby, A Ren, E Norton, M Leibowitz, S Ebrahimi, A Fower, H Fox, E Tato, M Ellul, G Sunderland, M Held, C Hetherington, F Nkongho, A Palmos, A Grundmann, J Stewart, M Griffiths, T Solomon, G Breen, A Coles, J Cavanagh, S Irani, A Vincent, L Taams, D Menon

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.

DOI: http://doi.org/10.1177/13524585231151951
Journal: Mult Scler
E-pub date: 1 Jun 2023
Authors: C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, D Horakova, R Alroughani, C Boz, F Patti, M Onofrj, A Lugaresi, S Eichau, M Girard, A Prat, P Duquette, B Yamout, SJ Khoury, SA Sajedi, R Turkoglu, A Altintas, O Skibina, K Buzzard, P Grammond, R Karabudak, A van der Walt, H Butzkueven, D Maimone, J Lechner-Scott, A Soysal, N John, J Prevost, D Spitaleri, C Ramo-Tello, O Gerlach, G Iuliano, M Foschi, R Ampapa, V van Pesch, M Barnett, N Shalaby, M D'hooghe, J Kuhle, MJ Sa, M Fabis-Pedrini, A Kermode, S Mrabet, R Gouider, S Hodgkinson, G Laureys, L Van Hijfte, R Macdonell, C Oreja-Guevara, E Cristiano, P McCombe, JL Sanchez-Menoyo, B Singhal, Y Blanco, S Hughes, J Garber, C Solaro, C McGuigan, B Taylor, K de Gans, M Habek, A Al-Asmi, S Mihaela, T Castillo Triviño, T Al-Harbi, JI Rojas, O Gray, D Khurana, B Van Wijmeersch, N Grigoriadis, J Inshasi, J Oh, E Aguera-Morales, Y Fragoso, F Moore, C Shaw, SM Baghbanian, N Shuey, B Willekens, TA Hardy, D Decoo, AP Sempere, D Field, R Wynford-Thomas, NG Cunniffe, I Roos, CB Malpas, AJ Coles, T Kalincik, JWL Brown

Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?

DOI: http://doi.org/10.1136/pn-2022-003531
Journal: Pract Neurol
E-pub date: 1 Apr 2023
Authors: G Brittain, AJ Coles, G Giovannoni, PA Muraro, J Palace, J Petrie, E Roldan, NJ Scolding, JA Snowden, B Sharrack

The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis.

DOI: http://doi.org/10.1038/s41380-022-01784-4
Journal: Mol Psychiatry
E-pub date: 1 Nov 2022
Authors: B Lennox, W Xiong, P Waters, A Coles, PB Jones, T Yeo, JTM May, K Yeeles, D Anthony, F Probert

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.

DOI: http://doi.org/10.1093/brain/awac321
Journal: Brain
E-pub date: 6 Sep 2022
Authors: EJ Needham, AL Ren, RJ Digby, EJ Norton, S Ebrahimi, JG Outtrim, DA Chatfield, AE Manktelow, MM Leibowitz, VFJ Newcombe, R Doffinger, G Barcenas-Morales, C Fonseca, MJ Taussig, RM Burnstein, RJ Samanta, C Dunai, N Sithole, NJ Ashton, H Zetterberg, M Gisslén, A Edén, E Marklund, PJM Openshaw, J Dunning, MJ Griffiths, J Cavanagh, G Breen, SR Irani, A Elmer, N Kingston, C Summers, JR Bradley, LS Taams, BD Michael, ET Bullmore, KGC Smith, PA Lyons, AJ Coles, DK Menon, Cambridge NeuroCOVID Group, CITIID-NIHR COVID-19 BioResource Collaboration, Cambridge NIHR Clinical Research Facility

Is stem cell transplantation safe and effective in multiple sclerosis?

DOI: http://doi.org/10.1136/bmj-2020-061514
Journal: BMJ
E-pub date: 9 Jun 2022
Authors: B Sharrack, J Petrie, A Coles, JA Snowden

Campath, clones and the cause of autoimmunity.

DOI: http://doi.org/10.1093/brain/awac162
Journal: Brain
E-pub date: 3 Jun 2022
Authors: A Coles

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.

DOI: http://doi.org/10.1177/13524585211046786
Journal: Mult Scler
E-pub date: 1 Jun 2022
Authors: ZG Georgieva, R Dӧffinger, D Kumararatne, AJ Coles, C McCarthy

Case reports in the Lancet: From neurophobia to global pandemics.

DOI: http://doi.org/10.1002/ccr3.5693
Journal: Clin Case Rep
E-pub date: 1 Apr 2022
Authors: BO Devoy, PJ Bennett, AJ Coles, HS Mousa

Susac’s syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.

DOI: http://doi.org/10.1007/s00415-021-10802-4
Journal: J Neurol
E-pub date: 1 Mar 2022
Authors: A Ahmed, ZQ Kok, A Coles, DJ Scoffings, SJ Crisp

Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

DOI: http://doi.org/10.1038/s42003-021-02721-x
Journal: Commun Biol
E-pub date: 14 Oct 2021
Authors: LB Jarvis, DB Rainbow, V Coppard, SK Howlett, Z Georgieva, JL Davies, HK Mullay, J Hester, T Ashmore, A Van Den Bosch, JT Grist, AJ Coles, HS Mousa, S Pluchino, KT Mahbubani, JL Griffin, K Saeb-Parsy, F Issa, L Peruzzotti-Jametti, LS Wicker, JL Jones

The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK.

DOI: http://doi.org/10.1016/j.msard.2021.103190
Journal: Mult Scler Relat Disord
E-pub date: 1 Oct 2021
Authors: L Fernandes, CM Allen, T Williams, E Tallantyre, N Evangelou, J Chataway, HL Ford, UK MS Trials and Registries Consortium investigators

Determinants of therapeutic lag in multiple sclerosis.

DOI: http://doi.org/10.1177/1352458520981300
Journal: Multiple Sclerosis Journal
E-pub date: 1 Oct 2021
Authors: I Roos, E Leray, F Frascoli, R Casey, JWL Brown, D Horakova, EK Havrdova, M Debouverie, M Trojano, F Patti, G Izquierdo, S Eichau, G Edan, A Prat, M Girard, P Duquette, M Onofrj, A Lugaresi, P Grammond, J Ciron, A Ruet, S Ozakbas, J De Seze, C Louapre, H Zephir, MJ Sá, P Sola, D Ferraro, P Labauge, G Defer, R Bergamaschi, C Lebrun-Frenay, C Boz, E Cartechini, T Moreau, D Laplaud, J Lechner-Scott, F Grand'Maison, O Gerlach, M Terzi, F Granella, R Alroughani, G Iuliano, V Van Pesch, B Van Wijmeersch, DLA Spitaleri, A Soysal, E Berger, J Prevost, E Aguera-Morales, P McCombe, T Castillo Triviño, P Clavelou, J Pelletier, R Turkoglu, B Stankoff, O Gout, E Thouvenot, O Heinzlef, Y Sidhom, R Gouider, T Csepany, B Bourre, A Al Khedr, O Casez, P Cabre, A Montcuquet, A Wahab, J-P Camdessanche, A Maurousset, I Patry, K Hankiewicz, C Pottier, N Maubeuge, C Labeyrie, C Nifle, A Coles, CB Malpas, S Vukusic, H Butzkueven, T Kalincik

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.

DOI: http://doi.org/10.1016/S0140-6736(21)01608-1
Journal: Lancet
E-pub date: 25 Sep 2021
Authors: RJ Perry, A Tamborska, B Singh, B Craven, R Marigold, P Arthur-Farraj, JM Yeo, L Zhang, G Hassan-Smith, M Jones, C Hutchcroft, E Hobson, D Warcel, D White, P Ferdinand, A Webb, T Solomon, M Scully, DJ Werring, C Roffe, CVT After Immunisation Against COVID-19 (CAIAC) collaborators

Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity

DOI: http://doi.org/10.1101/2021.12.03.21266112
Journal:
E-pub date: 1 Aug 2021
Authors: EJ Needham, AL Ren, RJ Digby, JG Outtrim, DA Chatfield, AE Manktelow, VFJ Newcombe, R Doffinger, G Barcenas-Morales, C Fonseca, MJ Taussig, RM Burnstein, C Dunai, N Sithole, NJ Ashton, H Zetterberg, M Gisslen, A Edén, E Marklund, MJ Griffiths, J Cavanagh, G Breen, SR Irani, A Elmer, N Kingston, JR Bradley, LS Taams, BD Michael, ET Bullmore, KGC Smith, PA Lyons, AJC Coles, DK Menon, the Cambridge NeuroCOVID Group, the NIHR COVID-19 BioResource, Cambridge NIHR Clinical Research Facility

The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro

DOI: http://doi.org/10.1101/2021.02.17.431344
Journal:
E-pub date: 1 Aug 2021
Authors: C Gaunt, D Rainbow, R Mackenzie, L Jarvis, H Mousa, N Cunniffe, Z Georgieva, W Brown, A Coles, J Jones

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

DOI: http://doi.org/10.1212/NXI.0000000000001008
Journal: Neurol Neuroimmunol Neuroinflamm
E-pub date: 1 Jul 2021
Authors: OA Abdel-Mannan, C Manchoon, T Rossor, J-C Southin, C Tur, W Brownlee, S Byrne, M Chitre, A Coles, R Forsyth, R Kneen, K Mankad, D Ram, S West, S Wright, E Wassmer, M Lim, O Ciccarelli, C Hemingway, Y Hacohen, UK-Childhood Inflammatory Disease Network

Neuroanatomical substrates of generalized brain dysfunction in COVID-19.

DOI: http://doi.org/10.1007/s00134-020-06241-w
Journal: Intensive Care Med
E-pub date: 1 Jan 2021
Authors: VFJ Newcombe, LRB Spindler, T Das, S Winzeck, K Allinson, EA Stamatakis, DK Menon, Cambridge NeuroCovid Imaging Collaborators

Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.

DOI: http://doi.org/10.1016/j.cct.2020.106009
Journal: Contemp Clin Trials
E-pub date: 31 Aug 2020
Authors: D Ontaneda, EC Tallantyre, PC Raza, SM Planchon, K Nakamura, D Miller, C Hersh, M Craner, C Bale, B Chaudhry, DD Gunzler, TE Love, S Gerry, A Coles, JA Cohen, N Evangelou

Parkinson’s disease and spirituality.

DOI: http://doi.org/10.3233/NRE-192947
Journal: NeuroRehabilitation
E-pub date: 1 Aug 2020
Authors: C Redfern, SL Mason, RA Barker, A Coles

Therapeutically expanded human regulatory T-cells are super- suppressive due to HIF1A induced expression of CD73.

DOI: http://doi.org/10.21203/rs.3.rs-92789/v1
Journal:
E-pub date: 1 Aug 2020
Authors: L Jarvis, D Rainbow, V Coppard, S Howlett, J Davies, H Mullay, J Hester, T Ashmore, AVD Bosch, J Grist, A Coles, H Mousa, S Pluchino, K Mahbubani, J Griffin, K Saeb-Parsy, F Issa, L Peruzzotti-Jametti, L Wicker, J Jones

Hyperpolarized 13C MRI: A novel approach for probing cerebral metabolism in health and neurological disease.

DOI: http://doi.org/10.1177/0271678X20909045
Journal: J Cereb Blood Flow Metab
E-pub date: 1 Jun 2020
Authors: JT Grist, JJ Miller, F Zaccagna, MA McLean, F Riemer, T Matys, DJ Tyler, C Laustsen, AJ Coles, FA Gallagher

Neurological Implications of COVID-19 Infections.

DOI: http://doi.org/10.1007/s12028-020-00978-4
Journal: Neurocrit Care
E-pub date: 1 Jun 2020
Authors: EJ Needham, SH-Y Chou, AJ Coles, DK Menon

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

DOI: http://doi.org/10.1177/1352458518796675
Journal: Mult Scler
E-pub date: 1 Oct 2019
Authors: S Wray, E Havrdova, DR Snydman, DL Arnold, JA Cohen, AJ Coles, H-P Hartung, KW Selmaj, HL Weiner, N Daizadeh, DH Margolin, MC Chirieac, DAS Compston

Keratinocyte growth factor impairs human thymic recovery from lymphopenia.

DOI: http://doi.org/10.1172/jci.insight.125377
Journal: JCI Insight
E-pub date: 7 May 2019
Authors: AJ Coles, L Azzopardi, O Kousin-Ezewu, HK Mullay, SA Thompson, L Jarvis, J Davies, S Howlett, D Rainbow, J Babar, TJ Sadler, JWL Brown, E Needham, K May, ZG Georgieva, AE Handel, S Maio, M Deadman, I Rota, G Holländer, S Dawson, D Jayne, R Seggewiss-Bernhardt, DC Douek, JD Isaacs, JL Jones

Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

DOI: http://doi.org/10.1016/j.neuroimage.2019.01.027
Journal: Neuroimage
E-pub date: 1 Apr 2019
Authors: JT Grist, MA McLean, F Riemer, RF Schulte, SS Deen, F Zaccagna, R Woitek, CJ Daniels, JD Kaggie, T Matys, I Patterson, R Slough, AB Gill, A Chhabra, R Eichenberger, M-C Laurent, A Comment, JH Gillard, AJ Coles, DJ Tyler, I Wilkinson, B Basu, DJ Lomas, MJ Graves, KM Brindle, FA Gallagher

A case of anaphylaxis to alemtuzumab.

DOI: http://doi.org/10.1007/s00415-019-09214-2
Journal: J Neurol
E-pub date: 1 Mar 2019
Authors: CJS Nye, A Wagner, O Kousin-Ezewu, JL Jones, AJ Coles

Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment.

DOI: http://doi.org/10.1111/ene.13759
Journal: Eur J Neurol
E-pub date: 1 Nov 2018
Authors: S Keddie, SJ Crisp, J Blackaby, A Cox, A Coles, M Hart, AJ Church, A Vincent, M Zandi, MP Lunn

Alemtuzumab as Treatment for Multiple Sclerosis.

DOI: http://doi.org/10.1101/cshperspect.a032029
Journal: Cold Spring Harb Perspect Med
E-pub date: 1 Oct 2018
Authors: S Katsavos, A Coles

Women on multiple sclerosis clinical trial steering committees.

DOI: http://doi.org/10.1002/ana.25306
Journal: Ann Neurol
E-pub date: 31 Aug 2018
Authors: J Moneim, A Coles, G Giovannoni, R Horne, O Carr

Hemophagocytic Lymphohistiocytosis in 2 Patients with Multiple Sclerosis Treated With Alemtuzumab

DOI: http://doi.org/10.1212/WNL.0000000000005420
Journal: Neurology
E-pub date: 1 May 2018
Authors: M Saarela, K Senthil, JL Jones, P Tienari, M Soilu-hanninen, L Airas, A Coles, J Saarinen

Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRI.

DOI: http://doi.org/10.1016/j.jns.2018.01.027
Journal: J Neurol Sci
E-pub date: 15 Apr 2018
Authors: JT Grist, F Riemer, MA McLean, T Matys, F Zaccagna, SF Hilborne, JP Mason, I Patterson, R Slough, J Kaggie, SS Deen, MJ Graves, JL Jones, AJ Coles, FA Gallagher

Authorship of phase 3 trials in multiple sclerosis.

DOI: http://doi.org/10.1002/ana.25203
Journal: Ann Neurol
E-pub date: 1 Apr 2018
Authors: A Coles

Hypothyroid ataxia complicating monoclonal antibody therapy.

DOI: http://doi.org/10.1136/practneurol-2017-001713
Journal: Pract Neurol
E-pub date: 1 Dec 2017
Authors: A Badran, C Moran, AJ Coles

A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers.

DOI: http://doi.org/10.1016/j.jneuroim.2017.08.009
Journal: J Neuroimmunol
E-pub date: 15 Nov 2017
Authors: AM Mori, S Agarwal, MWM Lee, M Rafferty, TA Hardy, A Coles, SW Reddel, DS Riminton

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

DOI: http://doi.org/10.1212/WNL.0000000000004354
Journal: Neurology
E-pub date: 12 Sep 2017
Authors: AJ Coles, JA Cohen, EJ Fox, G Giovannoni, H-P Hartung, E Havrdova, S Schippling, KW Selmaj, A Traboulsee, DAS Compston, DH Margolin, K Thangavelu, MC Chirieac, D Jody, P Xenopoulos, RJ Hogan, MA Panzara, DL Arnold, CARE-MS II and CAMMS03409 Investigators

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

DOI: http://doi.org/10.1212/WNL.0000000000004313
Journal: Neurology
E-pub date: 12 Sep 2017
Authors: E Havrdova, DL Arnold, JA Cohen, H-P Hartung, EJ Fox, G Giovannoni, S Schippling, KW Selmaj, A Traboulsee, DAS Compston, DH Margolin, K Thangavelu, CE Rodriguez, D Jody, RJ Hogan, P Xenopoulos, MA Panzara, AJ Coles, CARE-MS I and CAMMS03409 Investigators

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

DOI: http://doi.org/10.1212/WNL.0000000000003694
Journal: Neurology
E-pub date: 7 Mar 2017
Authors: J Barton, TA Hardy, S Riminton, SW Reddel, Y Barnett, A Coles, MH Barnett

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

DOI: http://doi.org/10.1212/WNL.0000000000003319
Journal: Neurology
E-pub date: 8 Nov 2016
Authors: G Giovannoni, JA Cohen, AJ Coles, H-P Hartung, E Havrdova, KW Selmaj, DH Margolin, SL Lake, SM Kaup, MA Panzara, DAS Compston, CARE-MS II Investigators

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

DOI: http://doi.org/10.1212/WNL.0000000000003169
Journal: Neurology
E-pub date: 4 Oct 2016
Authors: DL Arnold, E Fisher, VV Brinar, JA Cohen, AJ Coles, G Giovannoni, H-P Hartung, E Havrdova, KW Selmaj, M Stojanovic, HL Weiner, SL Lake, DH Margolin, DR Thomas, MA Panzara, DAS Compston, CARE-MS I and CARE-MS II Investigators

Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.

DOI: http://doi.org/10.1007/s00415-015-7925-y
Journal: JOURNAL OF NEUROLOGY
E-pub date: 1 Aug 2016
Authors: L Azzopardi, AL Cox, CL McCarthy, JL Jones, AJ Coles

Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.

DOI: http://doi.org/10.1016/j.jns.2016.02.025
Journal: J Neurol Sci
E-pub date: 15 Apr 2016
Authors: EJ Fox, D Wynn, AJ Coles, J Palmer, DH Margolin, CAMMS223 Investigators

Timing is everything in the treatment of multiple sclerosis.

DOI: http://doi.org/10.1136/bcr-2014-208960
Journal: BMJ Case Rep
E-pub date: 15 Apr 2015
Authors: CL McCarthy, G Giovannoni, AJ Coles

Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.

DOI: http://doi.org/10.1016/j.schres.2014.11.001
Journal: Schizophr Res
E-pub date: 1 Dec 2014
Authors: MS Zandi, JB Deakin, K Morris, C Buckley, L Jacobson, L Scoriels, AL Cox, AJ Coles, PB Jones, A Vincent, BR Lennox

Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy

DOI: http://doi.org/10.1016/j.jneuroim.2014.08.167
Journal: JOURNAL OF NEUROIMMUNOLOGY
E-pub date: 1 Aug 2014
Authors: LH Kasper, DL Arnold, AJ Coles, H-P Hartung, E Havrdova, KW Selmaj, J Palmer, DH Margolin, MA Panzara, DAS Compston

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

DOI: http://doi.org/10.1136/jnnp-2013-307042
Journal: J Neurol Neurosurg Psychiatry
E-pub date: 1 Jul 2014
Authors: L Azzopardi, SAJ Thompson, KE Harding, M Cossburn, N Robertson, A Compston, AJ Coles, JL Jones

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.

DOI: http://doi.org/10.1212/WNL.0000000000000520
Journal: Neurology
E-pub date: 17 Jun 2014
Authors: O Kousin-Ezewu, L Azzopardi, RA Parker, O Tuohy, A Compston, A Coles, J Jones

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.

DOI: http://doi.org/10.1016/j.jneuroim.2014.03.012
Journal: Journal of Neuroimmunology
E-pub date: 1 Jan 2014
Authors: JWL Brown, PJ Martin, JW Thorpe, AW Michell, AJ Coles, AL Cox, A Vincent, MS Zandi

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.

DOI: http://doi.org/10.1073/pnas.1313654110
Journal: Proc Natl Acad Sci U S A
E-pub date: 10 Dec 2013
Authors: JL Jones, SAJ Thompson, P Loh, JL Davies, OC Tuohy, AJ Curry, L Azzopardi, G Hill-Cawthorne, MT Fahey, A Compston, AJ Coles

First use of alemtuzumab in Balo’s concentric sclerosis: a case report.

DOI: http://doi.org/10.1177/1352458513498129
Journal: Mult Scler
E-pub date: 1 Oct 2013
Authors: JWL Brown, AJ Coles, JL Jones

Immune competence after alemtuzumab treatment of multiple sclerosis.

DOI: http://doi.org/10.1212/WNL.0b013e3182a35215
Journal: Neurology
E-pub date: 3 Sep 2013
Authors: CL McCarthy, O Tuohy, DAS Compston, DS Kumararatne, AJ Coles, JL Jones

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

DOI: http://doi.org/10.2147/DDDT.S32687
Journal: Drug Des Devel Ther
E-pub date: 1 Aug 2013
Authors: JWL Brown, AJ Coles

Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.

DOI: http://doi.org/10.1177/1352458512444915
Journal: Mult Scler
E-pub date: 1 Feb 2013
Authors: T Button, D Altmann, D Tozer, C Dalton, K Hunter, A Compston, A Coles, D Miller

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

DOI: http://doi.org/10.1016/S0140-6736(12)61769-3
Journal: The Lancet
E-pub date: 1 Nov 2012
Authors: JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, H-P Hartung, E Havrdova, KW Selmaj, HL Weiner, E Fisher, VV Brinar, G Giovannoni, M Stojanovic, BI Ertik, SL Lake, DH Margolin, MA Panzara, DAS Compston, CARE-MS I investigators

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

DOI: http://doi.org/10.1016/S0140-6736(12)61768-1
Journal: The Lancet
E-pub date: 1 Nov 2012
Authors: AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, H-P Hartung, E Havrdova, KW Selmaj, HL Weiner, T Miller, E Fisher, R Sandbrink, SL Lake, DH Margolin, P Oyuela, MA Panzara, DAS Compston, CARE-MS II investigators

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.

DOI: http://doi.org/10.1212/WNL.0b013e318228bec5
Journal: Neurology
E-pub date: 9 Aug 2011
Authors: M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, J Zajicek, N Scolding, M Boggild, T Pickersgill, Y Ben-Shlomo, A Coles, NP Robertson

An evolving case of headaches and strokes.

DOI: http://doi.org/10.1136/jnnp.2011.242206
Journal: Pract Neurol
E-pub date: 1 Apr 2011
Authors: AJ Shah, DP Breen, D Thomas, J Cross, A Coles, P Molyneux

Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans.

DOI: http://doi.org/10.1172/JCI43653
Journal: J Clin Invest
E-pub date: 1 Dec 2010
Authors: E Schoenmakers, M Agostini, C Mitchell, N Schoenmakers, L Papp, O Rajanayagam, R Padidela, L Ceron-Gutierrez, R Doffinger, C Prevosto, J Luan, S Montano, J Lu, M Castanet, N Clemons, M Groeneveld, P Castets, M Karbaschi, S Aitken, A Dixon, J Williams, I Campi, M Blount, H Burton, F Muntoni, D O'Donovan, A Dean, A Warren, C Brierley, D Baguley, P Guicheney, R Fitzgerald, A Coles, H Gaston, P Todd, A Holmgren, KK Khanna, M Cooke, R Semple, D Halsall, N Wareham, J Schwabe, L Grasso, P Beck-Peccoz, A Ogunko, M Dattani, M Gurnell, K Chatterjee

Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab

DOI: http://doi.org/10.1016/j.clim.2010.03.310
Journal: CLINICAL IMMUNOLOGY
E-pub date: 1 Aug 2010
Authors: J Jones, A Compston, A Coles